脊髓刺激市场：预测（2024-2029）

2022 年脊髓刺激市值为 24.28 亿美元。

细电缆（电极）和类似心律调节器的小型电池组构成了脊髓刺激疗法。发生器放置在皮下，通常靠近臀部或胃部，电极放置在脊髓与脊椎骨交汇处的硬膜外腔。遥控器的天线也位于机身外部。

全球老年人口不断增加

由于人口老化，脊髓刺激治疗市场预计将更加迅速地扩大。据世界卫生组织称，到2050年，大约有15亿人将超过65岁，其中大多数人将生活在新兴国家。在全球范围内，人们的寿命越来越长。现在大多数人预计能活到 60 多岁甚至更久。地球上每个国家的老年人口数量和比例都在增加。

到 2030 年，地球上六分之一的人将超过 60 岁。此时，60岁及以上人口比例将从2020年的10亿增加到14亿。因此，更容易患神经系统疾病等慢性疾病的人口老化正在推动脊髓刺激治疗市场的成长。

复杂性局部疼痛症候群的盛行率增加

肤色和体温的变化也是复杂性局部疼痛症候群的症状。所有这些变化都是由于调节血流和体温的神经受损而引起的微循环异常的结果。有些人可能会因外伤或受伤而出现软组织损伤、扭伤、骨折、四肢无法活动或出现上述所有情况。退化性疾病预计将以最快的速度发展，并推动脊髓刺激市场的发展。

提高脊髓刺激疗法的意识

随着个人和医疗保健专业人员对脊髓刺激治疗设备的认识不断提高，脊髓刺激治疗产业预计将会成长。随着患者越来越意识到脊髓刺激的好处，医疗保健专业人员正在推广脊髓刺激作为慢性疼痛和其他脊椎疾病的可行治疗选择。透过政府和保险公司提供的各种报销计划，患者可以负担得起脊髓刺激治疗设备。

微创方法和无线技术日益普及

脊髓刺激疗法越来越多地采用微创方法进行植入。这些方法缩短了恢復期，减少了手术创伤，并提高了患者的舒适度。此外，无线技术的进步使得远端控制脊髓刺激治疗成为可能。使用外部设备和智慧型手机应用程序，患者可以自订设备设定并使疼痛治疗变得更容易。这是脊髓刺激治疗市场的关键驱动因素。

技术改进

随着脊髓刺激设备技术的发展，脊髓刺激产业正在不断扩大。新的小工具添加了最新功能，包括更长的电池寿命、改进的编程等等。这些发展正在推动脊髓刺激治疗设备的使用，以改善患者的治疗效果。医疗设备产业为满足许多目标市场未满足的医疗需求而推出的创新脊髓刺激治疗设备预计将为脊髓刺激治疗市场的成长提供利润丰厚的机会。

人工智慧在脊髓刺激治疗的应用

脊髓刺激疗法使用人工智慧来提高刺激器发送的电脉衝的准确性。这是透过持续追踪和收集有关患者健康状况的资讯并使用该资讯来更改刺激器的设定来实现的。这可能会实现更个人化的治疗策略，并最终改善患者的治疗结果。透过使用人工智慧也可以减少与现有脊髓刺激疗法相关的副作用，这是脊髓刺激市场的关键成长要素。人工智慧被用来识别疾病、预测患者的治疗结果，甚至提案个人化的治疗计画。

在北美，脊髓刺激治疗市场预计将稳定成长。

由于慢性疼痛、下背痛和 CRPS 的发病率不断增加，预计北美将占据全球脊髓刺激治疗市场的大部分。此外，成熟的医疗设施、高素质医生的存在以及对脊髓刺激疗法的认识不断提高也推动了北美市场的发展。此外，由于技术改进产品的快速采用，预计脊髓刺激治疗市场也将快速成长。

美国预计将占最大市场占有率

美国是北美地区最大的脊髓刺激治疗行业，该行业的成长预计将受到产品发布以及与主要製造商和其他公司的商业化协议增加的推动。例如，波士顿科学公司最近推出的 WaveWriter Alpha 系列 SCS 设备预计将在 2021 年 1 月推动脊髓刺激疗法 (SCS) 市场的成长。

目录

第一章简介

• 市场概况
• 市场定义
• 调查范围
• 市场区隔
• 货币
• 先决条件
• 基准年和预测年时间表

第二章调查方法

• 调查资料
• 先决条件

第三章执行摘要

• 研究亮点

第四章市场动态

• 市场驱动因素
• 市场限制因素
• 波特五力分析
• 产业价值链分析

第五章脊髓刺激市场：副产品

• 介绍
• 可充电的
• 不可充电

第六章脊髓刺激市场：依疾病适应症

• 介绍
• 腰椎手术失败综合症
• 退化性疾病
• 复杂性局部疼痛症候群
• 蜘蛛网膜炎
• 其他的

第七章脊髓刺激治疗市场：依最终使用者分类

• 介绍
• 医院
• 门诊手术中心
• 专科诊所

第八章脊髓刺激市场：按地区

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 其他的
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章竞争环境及分析

• 主要企业及策略分析
• 市场占有率分析
• 合併、收购、协议和合作

第十章 公司简介

• Boston Scientific
• Medtronic
• Mayfield Clinic
• Johns Hopkins Medicine
• Cleveland Clinic
• Abbott
• Northern Pain Centre
• Biotronik
• Saluda Medical
• Vanderbilt Health

The spinal cord stimulation market was valued at US$2.428 billion in 2022.

Thin cables (the electrodes) and a tiny battery pack resembling a pacemaker make up spinal cord stimulators. The generator is positioned beneath the skin, often close to the buttocks or belly, and the electrodes are positioned in the epidural space, which is where the spinal cord and vertebrae meet. The remote control's antenna is also external to the body.

Growing geriatric population globally

The spinal cord stimulation market is expected to expand more quickly due to the aging population. Around 1.5 billion people will reach 65 years of age or older by 2050, according to the World Health Organization, with emerging countries contributing the majority of this rise. Globally, people are living longer. Today, the majority of individuals may anticipate living into their 60s and beyond. The number of older people and their share of the population are increasing in every nation on earth.

One in six individuals on the planet will be 60 or older by 2030. At this period the percentage of the population aged 60 years and older will climb from 1 billion in 2020 to 1.4 billion. Therefore, the aging population, which is more prone to chronic illnesses such as neurological diseases, is what is driving the spinal cord stimulation market growth.

Increasing prevalence of complex regional pain syndrome

Changes in skin tone and temperature are other symptoms of complex regional pain syndrome. All of these alterations are the result of aberrant microcirculation brought on by nerve injury that regulates blood flow and body temperature. Some people experience trauma or injury that results in soft tissue damage, sprains, fractures, limb immobilization, or all of the above. The degenerative disc disease is anticipated to develop at the quickest rate and fuel the spinal cord stimulation market.

Increase in awareness of spinal cord stimulation

The spinal cord stimulation industry is anticipated to grow as individuals and healthcare professionals become more aware of spinal cord stimulation devices. Healthcare professionals are advising these devices as a realistic therapy option for chronic pain and other spinal problems as patients are becoming more aware of their advantages. The cost of spinal cord stimulation devices has decreased for patients due to various reimbursement programs offered by several governments and insurance companies.

Rising popularity for minimally invasive approaches and wireless technologies

Spinal cord stimulators are increasingly being implanted using minimally invasive methods. These methods shorten recuperation durations, lessen surgical trauma, and improve patient comfort. Additionally, wireless technological advancements have made it possible to remotely program spinal cord stimulators. With the use of external devices or smartphone applications, patients may customize their device's settings for more easy pain treatment. This plays a key driver for the spinal cord stimulation market.

Enhancement in Technology

The spinal cord stimulation industry is expanding due to technical developments in spinal cord stimulation devices. Modern features like longer battery life, and better programming are being added to new gadgets. These developments are boosting the use of spinal cord stimulation devices and enhancing patient outcomes. Innovative spinal cord stimulation devices being introduced by the medical device sector to meet the unmet medical demands of a sizable target audience are anticipated to offer profitable chances for spinal cord stimulation market growth.

Use of AI in spinal cord stimulation

In spinal cord stimulation, AI is being utilized to improve the accuracy of the electrical impulses delivered by the stimulator. This is accomplished by continuously tracking and gathering information about the patient's health, and utilizing that information to modify the stimulator's settings. This enables a more individualized treatment strategy and could ultimately improve patient results. The number of adverse effects connected to existing spinal cord stimulator therapies may also be decreased with the use of AI which is a major growth driver for the spinal cord stimulation market. AI is being used to identify illnesses, forecast patient outcomes, and even suggest individualized treatment plans.

In North America, it is projected that the spinal cord stimulation market would grow steadily.

North America is anticipated to dominate the worldwide spinal cord stimulation market due to an increase in occurrences of chronic pain, failing back syndrome, and CRPS. Additionally, the existence of well-established healthcare facilities, the availability of highly qualified doctors, and rising awareness of spinal cord stimulation therapy will propel the North American market. Rapid spinal cord stimulation market growth is also anticipated as a result of the rapid adoption of technologically improved items.

The United States is anticipated to hold the maximum market share

The United States is the largest spinal cord stimulation industry in the North American region, and this industry's growth is predicted to be boosted by increased product launches and commercialization agreements with important manufacturers and other businesses. For instance, the spinal cord stimulation market growth of spinal cord stimulators (SCS) is anticipated to be boosted in January 2021 by the recent launch of Boston Scientific's WaveWriter Alpha line of SCS devices.

Market Key Developments

• In May 2023, according to a statement from Abbott, the U.S. Food and Drug Administration (FDA) authorized the use of its spinal cord stimulation (SCS) devices to treat people with persistent back pain.
• In October 2022, The Senza HFX iQ spinal cord stimulation (SCS) device, which includes AI, was authorized by the FDA.
• In August 2022, the new ProclaimTM Plus spinal cord stimulation (SCS) device from Abbott, which uses FlexBurst360TM treatment, gained FDA clearance.
• In January 2022, The U.S. Food and Drug Administration has approved the use of the rechargeable neurostimulators IntellisTM and VantaTM by Medtronic plc, a world leader in healthcare technology, to treat chronic pain brought on by diabetic peripheral neuropathy (DPN).

Segmentation:

By Product

• Rechargeable
• Non-rechargeable

By Disease Indication

• Failed Back Surgery Syndrome
• Degenerative Disc Disease
• Complex Regional Pain Syndrome
• Arachnoiditis
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. SPINAL CORD STIMULATION MARKET, BY PRODUCT

• 5.1. Introduction
• 5.2. Rechargeable
• 5.3. Non-rechargeable

6. SPINAL CORD STIMULATION MARKET, BY DISEASE INDICATION

• 6.1. Introduction
• 6.2. Failed Back Surgery Syndrome
• 6.3. Degenerative Disc Disease
• 6.4. Complex Regional Pain Syndrome
• 6.5. Arachnoiditis
• 6.6. Others

7. SPINAL CORD STIMULATION MARKET, BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Ambulatory Surgical Centers
• 7.4. Specialty Clinics

8. SPINAL CORD STIMULATION MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

• 10.1. Boston Scientific
• 10.2. Medtronic
• 10.3. Mayfield Clinic
• 10.4. Johns Hopkins Medicine
• 10.5. Cleveland Clinic
• 10.6. Abbott
• 10.7. Northern Pain Centre
• 10.8. Biotronik
• 10.9. Saluda Medical
• 10.10. Vanderbilt Health